

Table S1. Reported allosteric modulators of family A G protein-coupled receptors

Receptor	Modulator example(s)
GPCR Family A	
Adenosine A ₁	(PD 81723; PD 117975; PD 78416; PD 71605; LUF 5484; T-62); ¹ (VCP 520; VCP 333) ²
Adenosine A ₂	Amilorides
Adenosine A ₃	VU5455Z; VU8504Z; DU124183; [LUF6000 (compound 3 in paper)] ³ (AM 251; 2-arachidonylglycerol or 2-AG) ⁴
Adrenoceptor α ₁	Amilorides; benzodiazepines; conopeptide; p-TIA
Adrenoceptor α _{2A} , α _{2B}	Amilorides (and possibly sodium ions) ⁵
Adrenoceptor β ₂	Zinc ⁶
Cannabinoid CB ₁	Org27569 ⁷ ; Org27759 ⁷ ; PSNCBAM-1 ⁸ ; (JHW 007, RTI-371) ⁹
Chemokine CXCR1	Reparixin ¹⁰ ; SCH527123 ¹² (Compound 2-27-these inhibit CXCL8 that activates CXCR1-overall inhibitors of CXCR1) ¹¹ (SCH-479833 with an update on SCH527123) ^{12,14}
Chemokine CXCR2	Reparixin ¹⁰ ; SCH527123 ¹² ; SB656933 ¹³ ; DF2162 ¹³ ; (SCH-479833 with an update on SCH527123) ^{12,14}
Chemokine CXCR3	IP-10, I-TAC
Chemokine CXCR4	RSVM ¹⁵ ; ASLW ¹⁵ ; trichosanthin ¹⁶ ; plerixafor ¹⁷
Chemokine CCR1	BX-471 ¹⁸ ; CP-481-715 ¹⁹ ; UCB35625 ²⁰
Chemokine CCR3	UCB35625 ²⁰
Chemokine CCR5	Trichosanthin ¹⁶ ; TAK779 ²¹ ; Aplaviroc (also, AK602 and 873140 ^{21,22}); AK530 ²³ ; TAKK 220 ²⁴ ; SCH351125 (also, ancriviroc) ²⁵ ; vicriviroc ²⁶ ; maraviroc ²⁷
Dopamine D ₁	Zinc ²⁸
Dopamine D ₂	Amiloride ²⁹ , zinc,
Endothelin ET _A	aspirin, sodium salicylate ³⁰
Gonadotropin-releasing hormone receptor (GnRH)	Furan Derivative -1 (appears to be bitopic) ³¹ ; TAK-013 ³¹ ;
GH secretagogue	L-629,429, GHRP-6, MK-677 ³²
Luteinizing hormone	Org 41841 ³³ , [³ H]Org 43553 ³⁴
mAChR M1	Brucine; BQCA; TBPB; AC-42; 77-LH-28-1; N-DMC; VU0119498 ³⁵ staurosporine; ³⁶ ML071 ³⁷ ML169; ML137;
mAChR M2	McN-A-343; BR384; gallamine; ³⁸ W84; ³⁹ ; AC-42; 77-LH-28-1 ⁴⁰
mAChR M3	VU0119498 ³⁵
mAChR M4	LY2033298; VU0010010; VU0152099; ML108; Thiochrome; ³⁵ WIN 62577; ⁴¹ alcuronium; ML173, ML253, ML293
mAChR M5	ML129; VU0119498; ³⁵ VU0365114; VU0400265 ⁴² ; ML172, ML375
Neurokinin NK ₁	Heparin
Opioid μ, δ	Cannabidiol ⁴³
Purine P2 _{Y1}	2,2-o-pyridylisatogen tosylate
Serotonin 5HT _{1B/1D}	5HT-modulin
Serotonin 5HT _{2A} , 5HT ₂	Oleamine ⁴⁴
Serotonin 5HT _{2C}	Oleamine; ⁴⁴ PNU-69176E ⁴⁵

2-AG, 2-arachidonylglycerol; 5-HT, 5-hydroxytryptophan (serotonin), CCR, chemokine CC-motif receptor; CXCR, chemokine CXCR-motif receptor; GnRH, gonadotropin-releasing hormone; mAChR, muscarinic acetylcholine receptor

References

- ¹Aurelio, L. *et al.* 3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. *Bioorg Med Chem* 17, 7353-61 (2009)
- ²Valant, C. *et al.* Delineating the mode of action of adenosine A1 receptor allosteric modulators. *Mol Pharmacol* 78, 444-55 (2010).
- ³Kim, Y., de Castro, S., Gao, Z.G., Ijzerman, A.P. & Jacobson, K.A. Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. *J Med Chem* 52, 2098-108 (2009).
- ⁴Lane, J.R., Beukers, M.W., Mulder-Krieger, T. & Ijzerman, A.P. The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor. *Biochem Pharmacol* 79, 48-56 (2010).
- ⁵Pihlavisto, M., Sjöholm, B., Scheinin, M. & Wurster, S. Modulation of agonist binding to recombinant human alpha2-adrenoceptors by sodium ions. *Biochim Biophys Acta* 1448, 135-46 (1998).
- ⁶Swaminath, G., Steenhuis, J., Kobilka, B. & Lee, T.W. Allosteric modulation of beta2-adrenergic receptor by Zn(2+). *Mol Pharmacol* 61, 65-72 (2002).
- ⁷Price, M.R. *et al.* Allosteric modulation of the cannabinoid CB1 receptor. *Mol Pharmacol* 68, 1484-95 (2005).
- ⁸Horswill, J.G. *et al.* PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. *Br J Pharmacol* 152, 805-14 (2007).
- ⁹Navarro, H.A., Howard, J.L., Pollard, G.T. & Carroll, F.I. Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. *Br J Pharmacol* 156, 1178-84 (2009).
- ¹⁰Marsh, D.R. & Flemming, J.M. Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury. *Spinal Cord* 49, 337-44 (2011).
- ¹¹Sablone, M.R. *et al.* Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. *Bioorg Med Chem Lett* 19, 4026-30 (2009).
- ¹²Varney, M.L. *et al.* Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. *Cancer Lett* 300, 180-8 (2011).
- ¹³Chapman, R.W. *et al.* CXCR2 antagonists for the treatment of pulmonary disease. *Pharmacol Ther* 121, 55-68 (2009).
- ¹⁴Singh, S. *et al.* Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. *Clin Cancer Res* 15, 2380-6 (2009).
- ¹⁵Sachpatzidis, A. *et al.* Identification of allosteric peptide agonists of CXCR4. *J Biol Chem* 278, 896-907 (2003).
- ¹⁶Zhao, J. *et al.* Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors. *J Exp Med* 190, 101-11 (1999).
- ¹⁷Cashen, A.F., Nervi, B. & DiPersio, J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. *Future Oncol* 3, 19-27 (2007).
- ¹⁸Vaidehi, N. *et al.* Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. *J Biol Chem* 281, 27613-20 (2006).
- ¹⁹Gladue, R.P. *et al.* The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice. *J Immunol* 176, 3141-8 (2006).
- ²⁰Sabroe, I. *et al.* A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. *J Biol Chem* 275, 25985-92 (2000).
- ²¹Watson, C., Jenkinson, S., Kazmierski, W. & Kenakin, T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. *Mol Pharmacol* 67, 1268-82 (2005).

- ²²Nichols, W.G. *et al.* Hepatotoxicity observed in clinical trials of apilavirac (GW873140). *Antimicrob Agents Chemother* 52, 858-65 (2008).
- ²³Maeda, K. *et al.* Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 *in vitro*. *J Virol* 78, 8654-62 (2004).
- ²⁴Tremblay, C.L. *et al.* TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals *in vitro*. *Antimicrob Agents Chemother* 49, 3483-5 (2005).
- ²⁵Strizki, J.M. *et al.* SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection *in vitro* and *in vivo*. *Proc Natl Acad Sci U S A* 98, 12718-23 (2001).
- ²⁶Klibanov, O.M. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection. *Curr Opin Investig Drugs* 10, 845-59 (2009).
- ²⁷Meanwell, N.A. & Kadow, J.F. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. *Curr Opin Investig Drugs* 8, 669-81 (2007).
- ²⁸Schetz, J.A. & Sibley, D.R. Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. *J Neurochem* 68, 1990-7 (1997).
- ²⁹Hoare, S.R., Coldwell, M.C., Armstrong, D. & Strange, P.G. Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. *Br J Pharmacol* 130, 1045-59 (2000).
- ³⁰De Mey, J.G., Compeer, M.G., Lemkens, P. & Meens, M.J. ETA-receptor antagonists or allosteric modulators? *Trends Pharmacol Sci* 32, 345-51 (2011).
- ³¹Heitman, L.H., Ye, K., Oosterom, J. & Ijzerman, A.P. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. *Mol Pharmacol* 73, 1808-15 (2008).
- ³²Holst, B. *et al.* Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor. *Mol Pharmacol* 75, 44-59 (2009).
- ³³Janovick, J.A. *et al.* Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine. *Mol Cell Endocrinol* 298, 84-8 (2009).
- ³⁴Heitman, L.H. *et al.* [3H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor. *Mol Pharmacol* 73, 518-24 (2008).
- ³⁵Conn, P.J., Jones, C.K. & Lindsley, C.W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. *Trends Pharmacol Sci* 30, 148-55 (2009).
- ³⁶Gregory, K.J., Sexton, P.M. & Christopoulos, A. Allosteric modulation of muscarinic acetylcholine receptors. *Curr Neuropharmacol* 5, 157-67 (2007).
- ³⁷Reid, P.R. *et al.* Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. *Bioorg Med Chem Lett* 21, 2697-701 (2011).
- ³⁸Suga, H. & Ehlert, F.J. Investigating the interaction of McN-A-343 with the M2 muscarinic receptor using its nitrogen mustard derivative. *Biochem Pharmacol* 79, 1025-35 (2010).
- ³⁹Maier-Peuschel, M. *et al.* A fluorescence resonance energy transfer-based M2 muscarinic receptor sensor reveals rapid kinetics of allosteric modulation. *J Biol Chem* 285, 8793-800 (2010).
- ⁴⁰May, L.T. *et al.* Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. *Mol Pharmacol* 72, 463-76 (2007).
- ⁴¹Lanzafame, A.A., Sexton, P.M. & Christopoulos, A. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. *Mol Pharmacol* 70, 736-46 (2006).
- ⁴²Bridges, T.M., Kennedy, J.P., Hopkins, C.R., Conn, P.J. & Lindsley, C.W. Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. *Bioorg Med Chem Lett* 20, 5617-22 (2010).
- ⁴³Kathmann, M., Flau, K., Redmer, A., Trankle, C. & Schlicker, E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. *Naunyn Schmiedebergs Arch Pharmacol* 372, 354-61 (2006).

- ⁴⁴Thomas, E.A., Carson, M.J., Neal, M.J. & Sutcliffe, J.G. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. *Proc Natl Acad Sci U S A* 94, 14115-9 (1997).
- ⁴⁵Im, W.B., Chio, C.L., Alberts, G.L. & Dinh, D.M. Positive allosteric modulator of the human 5-HT_{2C} receptor. *Mol Pharmacol* 64, 78-84 (2003).